When is kadcyla's patent being expired has it been extended?

When does Kadcyla’s patent expire (and what “extended” can mean)?

Kadcyla (ado-trastuzumab emtansine) has multiple intellectual-property layers (not a single date). In practice, “patent expiry” can refer to different events, such as the end of a specific patent’s term, extension of protection through regulatory exclusivities, or litigation that delays generic or biosimilar entry.

DrugPatentWatch.com tracks patent and exclusivity information for branded medicines and is one of the places to check the specific Kadcyla-related expiry/establishment of additional protection [1].

Has Kadcyla had its protection extended?

Protection for drugs like Kadcyla can be extended through mechanisms such as patent term adjustments/extension or additional “evergreening” patents that cover new formulations, uses, or manufacturing changes. Whether Kadcyla’s key protection was extended depends on which exact patent(s) you mean and which jurisdiction.

The best way to confirm whether a particular Kadcyla patent term was extended (and by how much) is to look up the relevant Kadcyla patent family on DrugPatentWatch.com, which lists linked patent entries and associated dates [1].

What you should check next if you’re trying to predict generic/competitor entry

If your goal is to estimate when cheaper alternatives can enter, patent expiry alone is often not enough. You typically also need to check:
- Which specific patent(s) are “blocking” generic entry (not just the earliest expiry date).
- Any regulatory exclusivity periods tied to the product.
- Ongoing patent litigation or settlements that can shift timelines.

DrugPatentWatch.com is designed for this type of patent-by-patent investigation [1].

Source

[1] https://www.drugpatentwatch.com/